Mylan NV could face decline in profitability in 2017 and 2018

Mylan NV faces decline in profitability in 2017 and 2018

Generic drug maker Mylan NV admitted on Wednesday that delays in the launch of some of its new drugs in addition to eroding prices for generics in the U.S. could hurt its profitability in 2017 as well as in 2018.

Due to uncertain U.S. regulatory environment, Mylan NV pushed back the launch of its key drugs in the U.S. to 2018.

David Maris, an analyst with Wells Fargo, said, “It’s clear they can’t achieve it. The fact they can’t make that tells you things must be bad. The $6 number has had a long and questionable history in my book.”

The launches, which the company pushed back to next year, include those of the company’s generic version of Teva’s multiple sclerosis drug Copaxone and GlaxoSmithKline’s (GSK’s) blockbuster Advair.

In the after-hours trading, stock in Mylan NV slipped nearly 7 per cent to hit its nearly four-year low. Since last week, the generic drug maker’s stock has shed nearly 20 per cent of its market value.

News: 
Location: 
Company: 

Popular Stories

Ryanair alleges conspiracy between Lufthansa management and Air Berlin

Alleging a conspiracy between Lufthansa management... Read More

Nvidia shares fall on lower-than-expected quarterly revenue

Stock price of Nvidia Corporation slipped on... Read More

Mylan NV faces decline in profitability in 2017 and 2018

Generic drug maker Mylan NV admitted on Wednesday... Read More

European stocks slide amid U.S.-North Korea tensions

European stocks slipped sharply on Wednesday as... Read More

China’s export-import growth slips

China suffered a minor setback in the growth of its... Read More

Renault signs new JV in Iran

French carmaker Renault has confirmed that it has... Read More